While AI dominates headlines, GLP-1s offer more immediate and tangible improvements to human health and quality of life. The market impact of solving pervasive health crises like obesity, addiction, and heart disease may ultimately dwarf the current perceived value of AI.

The success of GLP-1s like Ozempic, which address weight loss, addiction, and metabolic fitness, has made the public more receptive to longevity drugs. People now better understand how a single drug targeting a core mechanism (like metabolic health) can have widespread, seemingly magical downstream benefits.

Originally for diabetes, GLP-1s' broad positive effects on inflammation, heart, and brain function position them as the first mainstream drugs for human enhancement and longevity, moving beyond simple disease management.

Peter Diamandis frames GLP-1s not just as weight-loss drugs but as the "very first longevity drug." By addressing metabolic unhealthiness and excess visceral fat—known life-shortening factors—these drugs represent a major step towards extending human healthspan, with more advanced versions already in development.

Weight-loss drugs like Ozempic have moved from a niche medical treatment to a mainstream phenomenon, with new data showing 15.2% of all American women are now taking them. This rapid, large-scale adoption signifies a major public health shift that will have downstream effects on the food, fitness, and healthcare industries.

Beyond direct physiological changes, GLP-1s help correct underlying physiology, which restores the mental and physical resources needed to maintain fundamentals like sleep, exercise, and nutrition. This secondary effect can be more profound than the drug's primary action.

Scott Galloway argues GLP-1 drugs (like Ozempic) will have a greater societal impact than AI. By tackling obesity, they could halve U.S. healthcare costs, help solve the deficit, and even curb addictions, making them a profoundly transformative technology.

The biotech industry is currently a "disease industry." The largest future markets, like GLP-1 drugs for weight loss, will target healthy consumers seeking enhancements in lifespan, sleep, or appearance. This represents a fundamental shift to a consumer-driven, preventative health model.

The transition to oral GLP-1 therapies is a significant market expander, not just a convenience upgrade. Nearly 80% of patients starting oral medications are new to the drug category, indicating a substantial increase in the addressable patient pool rather than simple conversion of existing users.